Introduction:
The interferon consensus sequence binding protein (ICSBP or IRF8) is an interferon regulatory factor which regulates multiple aspects of myelopoiesis. ICSBP was cloned by homology to interferon regulatory factors 1 and 2 (IRF1 and IRF2) (1) . However, unlike these ubiquitous proteins, ICSBP is expressed exclusively in myeloid and B cells. Similar to other IRF proteins, ICSBP interacts with cis elements containing ISRE, PRDI, or composite ets/IRF consensus sequences (2) . ICSBP either activates or represses target-gene transcription, depending upon the sequence of the cis element and the cellular context (3) .
The first identified ICSBP target-genes encoded proteins involved in the inflammatory response.
For example, ICSBP activates transcription of genes encoding the NADPHoxidase proteins gp91
PHOX and p67 PHOX , the Toll like receptor 4, IL18 and IL12 in differentiating myeloid cells (4) (5) (6) (7) (8) . Transcriptional activation involves binding of ICSBP to the cis elements of these genes via DNA-bound PU.1 and/or another IRF. This interaction requires phosphorylation of conserved tyrosine residues in the IRF-domain of ICSBP (9) .
Since ICSBP is tyrosinephosphorylated during myelopoiesis, this provides a mechanism for differentiation-stage-specific transcription of such genes (9, 10) . ICSBP also represses transcription of the gene encoding 3'5' oligoadenylate synthase (OAS) during macrophage differentiation (11) . Therefore, ICSBP may downregulate some phagocyte functions during differentiation of monocytes to macrophages; a process necessary to prevent tissue damage.
To better understand the role of ICSBP in myelopoiesis, an ICSBP-deficient murine model was generated (12) . These mice exhibit specific defects in immune function, as anticipated. In addition, 100% of homozygous ICSBP knock-out mice develop a myeloproliferative disorder (MPD).
This MPD is characterized by leukocytosis with mature appearing neutrophils which accumulate in the bone marrow and tissues (12) . Acute myeloid leukemia (AML), develops in 80% of ICSBP-/-mice by 6 mos (12) . Further studies indicate that myeloid cells from ICSBP-/-mice are resistant to apoptosis and hypersensitive to various cytokines, including GM-CSF, M-CSF and SCF (13, 14) . These results imply the existence of a set of ICSBP target-genes that regulate proliferation and apoptosis. ICSBP-expression was also investigated in human myeloid malignancies.
A decrease in ICSBP mRNA is found in bone marrow cells from subjects with chronic myeloid leukemia (CML) in comparison to normal (15, 16) . ICSBP-expression is also decreased in CD34+ bone marrow cells from a poor prognosis subset of subjects with therapy related myelodysplasia and AML (tMDS/AML) (17) .
To identify target-genes involved in the leukemia-suppressor function of ICSBP, we screened a CpG island microarray with chromatin that co-immunoprecipitated with ICSBP from myeloid cells (14) . As previously reported, we identified the gene encoding Neurofibromin 1 (Nf1) as an ICSBP target (10, 14, 18) . Since Nf1 is a Ras-GAP, these results provide a mechanism for cytokine hypersensitivity in ICSBP-deficient cells.
In the current studies, we identified PTPN13 as an ICSBP target-gene. PTPN13 encodes Fas Associated Phosphatase-1 (Fap-1): a protein tyrosine phosphatase (PTP) which antagonizes Fas-induced apoptosis (19, 20) . Since Fas is important for apoptosis of mature phagocytic cells, this result had potential significance for ICSBPdeficient myelopoiesis (21) . Previous studies demonstrated that Fap-1 inhibits Fas-induced apoptosis by dephosphorylating Fas and by inhibiting cell membrane trafficking (22) . If ICSBP represses PTPN13 transcription, Fap-1 expression would increase in ICSBP-deficient cells. The resultant Fas-resistance might provide a mechanism for accumulation of phagocytes in the ICSBP-deficient murine model and in human diseases such as CML.
Fas-resistance correlates with increased Fap-1-expression in some leukemia cell lines (23) . Fasexpression and/or function is associated with treatment resistance and prognosis in AML (24) . Also, Fas-resistance may result in persistence of malignant clones during treatment of CML (25) . Therefore, identification of PTPN13 as an ICSBP target-gene would have implications for understanding the phenotype of ICSBP-deficient myeloid malignancies and might suggest therapeutic approaches to such diseases.
Materials and Methods:
Plasmids:
Protein expression vectors:
The ICSBP cDNA was obtained from Dr. Ben Zion-Levi (Technion, Haifa, Israel), the full length cDNA was generated by PCR and subcloned into the mammalian expression vector pcDNA and the pMSCVpuro retroviral vector (Stratagene, La Jolla, CA) (14) . A mutant form of ICSBP with conserved IRF-domain tyrosine residues changed to phenylalanine has been previously described (Y92/95F ICSBP) (9) . shRNA expression vectors: ICSBP specific shRNA and scrambled control sequences were designed with the assistance of the Promega website.
Double stranded oligonucleotides representing the complementary sequences separated by a hairpin loop were subcloned into the pLKO.1puro vector (a gift from Dr. Kathy Rundell, Northwestern University, Chicago). Several sequences were tested and the most efficient for ICSBP-suppression (and scrambled negative control) were used in the experiments.
PTPN13 reporter constructs: Various fragments of the PTPN13 5' flank were obtained from U937 chromatin by genomic PCR. The fragments were sequenced on both strands to ensure identity with the published sequence and subcloned into the pCATE reporter vector (Promega, Madison, WI).
Oligonucleotides: Oligonucleotides were custom synthesized by MWG Biotech (Piedmont, NC). Double stranded oligonucleotides used in EMSA and/or DNAaffinity purification experiments represented the -587 to -627 bp sequence of the PTPN13 promoter (5'-CTCCCGGAGTCTGTTTCTAATTTCTGCAAA TGATTGTGG-3': the ISRE-like sequence is underlined), an ISRE consensus sequence (5'-GGATCCAGAAAGCGAAAGTGGTCTGTAAA TCCCTCGAG-3'), a mutant form of the PRDIconsensus which does not bind ICSBP (5'-TGTCTTTGTCTTTGTCTT-3'), and an irrelevant oligo with a CCAAT box from the Beta globin gene (5'-CCTGGTAAGGGCCAATCTGCTCAC-3'). Oligonucleotides used to amplify PTPN13 sequences by quantitative real time PCR were -627 to -613 (5'-CTCCCGGAGTCTG-3') and -602 to -587 (5'-TGCAAATGATTGTGG-3').
Myeloid cell line culture:
The human myelomonocytic leukemia cell line U937 (26) Center, Northwestern University, Chicago). Cells were maintained as described (14) . U937 or KG1 cells were treated for 48 hrs with 500 U per ml human recombinant IFNγ for differentiation (Roche, Indianapolis, IN).
Murine bone marrow culture: Animal studies were performed according to a protocol approved by the Animal Care and Use Committees of Northwestern University and Jesse Brown VA Medical Center. Bone marrow mononuclear cells were obtained from the femurs of Wt or ICSBP-/-C57/BL6 mice. Sca1+ cells were separated using the Miltenyi magnetic bead system (Miltenyi Biotechnology, Auburn, CA). Bi-potential myeloid progenitor cells were cultured (at a concentration of 2 X 10 5 cells per ml) for 48 hrs in DME media supplemented with 10% fetal calf serum, 1% pen-strep, 10 ng/ml murine GM-CSF (R & D Systems Inc., Minneapolis, MN) and 10 ng/ml murine recombinant IL-3 (R & D Systems Inc.). Some ICSBP-/-myeloid progenitors were transduced with a retroviral vector to express ICSBP or Y92/05F ICSBP or empty vector control, as described (10) . Cells were either maintained in GM-CSF+IL3 for 48 hrs, or were differentiated over 72 hrs in 10 ng/ml of G-CSF (granulocyte) or 10 ng/ml of murine M-CSF (monocyte) + 500 U/ml of murine IFNγ for the last 24 hrs.
Chromatin co-immunoprecipitation and CpG island microarray screening: U937 cells were cultured with or without IFNγ for 48 hrs (14) . Cells were incubated briefly in media supplemented with formaldehyde and cell lysates were sonicated to generate chromatin fragments with an average size of 2.0 kb (27) . Lysates were immunoprecipitated with either ICSBP anti-serum or pre-immune serum (10) . Antibody to ICSBP (and control pre-immune serum) was a kind gift of Dr. Stephanie Vogel (University of Maryland, Baltimore MD). Chromatin was PCR-amplified, as described (27) . Several batches of immunoprecipitated, amplified chromatin were combined for each experiment.
Aliquots of ICSBP-specific and pre-immune serum control precipitated, amplified chromatin were labeled with Cy3 or Cy5 by the random primer method (with dye swapping to control for differences in incorporation efficiency). Labeled DNA was used to probe a CpG island microarray, as described (27) . Microarrays were obtained from the Microarray Center, University Health Network (Ontario Cancer Institute, Ontario, Canada). "Spots" with 3 fold enhancement in ICSBP specific vs. control serum precipitated chromatin in three independent hybridization experiments were further considered. Arrays were scanned using an Agilent microarray scanner (G2565BA, Wilmington, ED) and feature intensity statistics were extracted using GenePix (Molecular Devices, Union City, CA).
The GenBank accession number from the array was used to search the NCBI human genome data base for adjacent genes.
Some co-precipitated chromatin was analyzed by PCR for co-precipitation of the PTPN13 gene. For these experiments, total input chromatin (not precipitated) was a positive control and chromatin precipitated by pre-immune serum was a negative control.
PCR products were analyzed by acrylamide gel electrophoresis or real time PCR.
Quantitative real time PCR: For determining mRNA expression: RNA was isolated using the Triazol reagent (Gibco-BRL, Gaithersburg MD) and tested for integrity by denaturing gel electrophoresis. Primers were designed with Applied Biosystems software and real time PCR was performed using SYBR green according to the "standard curve" method. Result were normalized to 18S.
For quantifying chromatin immunoprecipitation: Chromatin which co-precipitated with ICSBP antibody or pre-immune serum was amplified with primers flanking the ICSBPbinding cis element in the PTPN13 promoter (-669 to -646: 5'-GTCGTGCTTGCACAGCTCCGCTCT-3' and -512 to -489:
Results were normalized to PCR reactions with total, non-precipitated chromatin to control for differences in DNA abundance between samples. Myeloid cell line transfections and reporter gene assays:
Stable transfectant cell lines: KG1 cells were transfected by electroporation with equal amounts of an ICSBP expression vector or empty vector control (ICSBP/pcDNAamp or pcDNAamp) plus a vector with a neomycin phospho transferase cassette (pSRα) (30 μg each). Stable pools of cells were selected in G418 (0.5 mg/ml) and aliquots of cells were tested for ICSBP-expression by Western blot.
Other KG1 cells were transfected by electroporation with a construct to express an ICSBP specific shRNA or scrambled control shRNA using the pLKO.1puro vector. Stable pools of transfected cells were selected in puromycin (1.2 μg/ml) and tested for ICSBP expression by Western blot.
Transient transfections for reporter gene assays: U937 cells (32 x 10 6 /ml) were transfected with a vector to express ICSBP or vector control (50 μg) and reporter constructs with 2.0 kb, 1.3 kb, 670 bp or 500 bp of PTPN13 3' flank in the pCATE reporter vector or empty vector control (70 μg). Cells were co-transfected with CMV/β-gal reporter to control for transfection efficiency. Transfectants were assayed for CAT and β-galactosidase expression after 48 hrs, as described (10, 14) .
Apoptosis assays: Apoptosis assays were performed using annexin V/propidium iodide (PI) double staining. The cells were washed with culture medium and adjusted to a concentration of 1 x 10 6 cells/ml, incubated with Annexin-V-FITC solution (2.5 µg/ml) and PI (12.5 µg/ml) on ice for 15 min, and analyzed on a Becton-Dickinson FACScan flow cytometry (Cambridge, MA).
U937 and KG1 cells: Cells were cultured for 48 hrs with or without IFNγ (500 U/ml). Cells were incubated with Fas-agonist antibody CH11 or control, as described (28) . In some experiments, cells were incubated for the last 12 hrs with SLV peptide (or control VLS peptide) to disrupt Fas:Fap-1 interaction (29) .
Murine bone marrow myeloid cells: Murine bone marrow myeloid progenitors from Wt or ICSBP-/-cells were incubated in GM-CSF, or differentiated with M-CSF or G-CSF as described above + 500 U/ml of IFNγ for the last 24 hrs. Cells were incubated with Fas-agonist antibody, as above. In some experiments, Fas-antibody treated cells were incubated with SLV peptide or VLS peptide.
Immuno-precipitation and (30) with protease inhibitors, as described (10, 14) .
In vitro DNA-binding assays: DNA-affinity purification assays (DAPA): Nuclear proteins (300 μg) were incubated with biotin-labeled ds oligonucleotide probe representing the -587 to -627 bp PTPN13 promoter sequence or a non-ICSBP-binding PRDImutant sequence overnight in DAPA buffer (25 mM HEPES (pH 7.6), 60 mM KCl, 5 mM MgCl 2 , 7.5% glycerol, 0.1 mM EDTA, 1 mM DTT, and 0.25% Triton X-100). The DNA-protein complexes were precipitated with 50 μL of a 50% slurry of neutravidin-coated agarose beads (Pierce, Rockford, IL, USA). Proteins bound to the beads were eluted, separated by SDS-PAGE (10% acrylamide) and transferred to nitrocellulose. Western blots were probed with an antibody to ICSBP obtained from Santa Cruz Biotech (Santa Cruz, CA).
Electrophoretic mobility assays: Oligonucleotides probes were prepared, EMSA and antibody supershift assays were performed as described (10, 14) . Each assay was repeated with at least three different batches of nuclear proteins and representative experiments are shown. In some experiments, binding assays were preincubated with unlabeled ds oligonucleotides competitors.
In other experiments, binding reactions were pre-incubated with an ICSBPantibody or an irrelevant antibody to the DNA binding domain of the yeast Gal4 transcription factor (Santa Cruz Biotech, Santa Cruz, CA). Each experiment was repeated several times with at least three different batches of nuclear proteins. Equal loading for nuclear proteins was determined in control EMSA with a probe representing a classical CCAAT box from the alpha globin gene.
Genomic Sequence Analysis: Conserved genomic sequences and consensus sequences for IRF protein DNA-binding were identified using the VISTA software (Genomics Division of the Lawrence Berkley National Laboratory (Berkley, CA) (31) (32) (33) .
Statistical Analysis: Statistical significance was determined by Student's t-test and ANOVA methods using the SigmaPlot and SigmaStat software.
Results:
Identification of PTPN13 as an ICSBP-targetgene:
To identifying target-genes involved in the leukemia-suppressor function of ICSBP, we screened a CpG island microarray with ICSBP-coimmunoprecipitating chromatin. We used the U937 myeloid leukemia cell line in these studies. These cells undergo differentiation in response to various cytokines, including IFNγ (26) . Over a 24 hr period, differentiating U937 cells acquire characteristics of mature phagocytes, including respiratory burst activity and phagocytosis (4, 5) . Differentiation of U937 cells is also characterized by cell cycle arrest by 24 hrs, and programmed cell death over 48-96 hours. U937 cells express a number of interferon regulatory factors (IRFs), including ICSBP. Previous studies demonstrated that IRF1, IRF2 and ICSBP are tyrosine phosphorylated during differentiation of either U937 cells or primary myeloid progenitor cells (9, 10, 18) . Therefore, U937 cells represented a reasonable model to study events that are influenced by ICSBP during myelopoiesis.
To identify differentiation-stage-specific interactions of ICSBP with potential target-genes, human CpG island microarrays were screened with chromatin that co-immunoprecipitated with ICSBP from U937 cells with or without 48 hrs of IFNγ-differentiation.
Prior to immunoprecipitation, lysates were sonicated to generate chromatin fragments of 2.0 kb or less (27) . Using this technique, we identified a number of putative ICSBP-target-genes involved in the inflammatory response (Table 1 ). This was consistent with the known role of ICSBP in regulating phagocyte and B-cell effector genes. We also identified a CpG island in the 5' flank of the PTPN13 gene in experiments with co-precipitating chromatin from differentiated cells. This gene encodes Fasassociated-phosphatase 1 (Fap-1), a protein that antagonizes Fas-induced apoptosis. This was of interest, because ICSBP-deficiency is associated with apoptosis resistance.
The identified CpG island was between -875 and -2230 bp from the PTPN13 transcription start site (TSS), thereby identifying a potential ICSBPbinding-site within the proximal 4.0 kb of the 5' flank ( Figure 1A ).
To assist in identifying functionally significant cis elements, we analyzed the PTPN13 gene for conserved sequences. This analysis determined that the human and murine PTPN13 sequences were highly conserved throughout the coding region and within the proximal 2.0 kb of PTPN13 5' flank ( Figure 1B ). Sequence homology between the two species decreased rapidly beyond 3.0 kb 5' of the TSS. We searched the proximal 4.0 kb of PTPN13 5' flank for IRF protein DNA-binding site consensus sequences. We identified 8 potential binding-sites, all located within the proximal 700 bp.
To verify these results, independent chromatin immuno-precipitation experiments were performed. For these studies, chromatin was coprecipitated from lysates of differentiated U937 cells with ICSBP-antibody or control pre-immune serum. Precipitated chromatin was analyzed by PCR with primers representing various sequences in the PTPN13 5' flank. PCR products were sized by acrylamide gel electrophoresis. We found that 2.0 or 1.0 kb of the proximal PTPN13 5' flank specifically co-precipitated with ICSBP, but the proximal 500bp did not ( Figure 1C ). Additional PCR primers were designed to further localize the binding-site. ICSBP-co-precipitating chromatin was amplified by primers for the proximal 670 bp, but not 600 bp, of PTPN13 5' flank ( Figure 1C ). This region included one of the IRF-binding consensus sequences identified by data base search. This sequence was homologous to ISRE or composite ets/IRF consensus sequences (-602 to -612: 5'-GAAATTAGAAA-3', compared to ISRE: 5'-GAAANNGAAA-3', or ets/IRF: 5'-GAA(A/G)TGNNA-3').
We also investigated more distal sequences. We found that ICSBP-co-precipitating chromatin was not amplified by primers flanking the 670 bp to 2.0 kb sequence ( Figure 1C ), nor the sequence between 2.0 and 4.0 kb (not shown). These results suggested that ICSBP interacts with an IRFbinding consensus sequence in the proximal PTPN13 promoter. However, a role for ICSBP in Fap-1-expression had not been previously described. Therefore, we investigated whether Fap-1-expression was ICSBP-dependent.
ICSBP-expression inversely correlated with Fap-1-expression in myeloid cells:
In previous studies, Fas-sensitivity and Fap-1 expression were determined in various leukemia cell lines (23) . U937 cells were found to be relatively Fas-resistant with abundant Fap-1-expression. In contrast, KG1 myeloid cells were relatively Fas-sensitive with lower levels of Fap-1 (23) . Since ICSBP-deficient cells are resistant to apoptosis (21), we investigated whether expression of ICSBP and Fap-1 were inversely correlated in U937 cells vs. KG1 cells. We found that ICSBP protein was relatively more abundant and Fap-1 protein relatively less abundant in KG1 cells in comparison to U937 cells ( Figure 2A ). We also found that Fap-1-expression decreased in both lines during differentiation. These studies were repeated at least three times and representative results are shown. As in our previous studies, ICSBP protein-abundance was not altered by differentiation of U937 or KG1 cells (9, 10) . Therefore, ICSBP-expression levels did not explain decreased Fap-1-expression during differentiation. This is addressed further below.
U937 and KG1 are leukemia cell lines which might be anticipated to have abnormalities in a number of signaling pathways. In order to directly determine the impact of ICSBP on Fap-1-expression, stable KG1 transfectants were generated in which ICSBP-expression was specifically manipulated. In initial studies, KG1 cells were transfected with a vector to overexpress ICSBP (or empty expression vector). We found that ICSBP-overexpression decreased Fap-1-expression and increased Fas-tyrosinephosphorylation in these cells ( Figure 2B ). In the converse experiment, stable KG1 transfectant pools were generated with a vector to express an ICSBP-specific shRNA (or a scrambled control shRNA) ( Figure 2B ). We found that decreased ICSBP-expression correlated with increased Fap-1-expression and decreased Fas-tyrosinephosphorylation. Three independent transfectant pools were generated for each of these constructs and blots were repeated several times for each pool.
A representative blot from a single experiment is shown. Therefore, perturbation of ICSBP-expression altered Fap-1-expression and Fas-phosphorylation in myeloid cell lines.
We also investigated the association between expression of ICSBP and Fap-1 in a nontransformed model of myeloid differentiation. For these studies, Sca1+ cells were isolated from the bone marrow of ICSBP-/-mice or Wt control litter mates and myeloid progenitors were cultured in GM-CSF, IL3 and SCF.
Some cells were differentiated to granulocytes with G-CSF, or to monocytes with M-CSF. IFNγ was added to some cultures to induce terminal differentiation. (12, 14) . These results indicated a block in terminal differentiation in ICSBP-/-cells, as anticipated based on known target-genes (4-8).
Gene expression was studied in these cells using quantitative real time PCR. Each study was performed three times in duplicate. We found slightly more Fap-1 mRNA in ICSBP-/-myeloid progenitors in comparison to Wt (p=0.24, n=6) ( Figure 2C ). The amount of Fap-1 mRNA decreased significantly in Wt progenitor cells upon differentiation with G-CSF or M-CSF (p<0.005, n=6). In contrast, Fap-1-expression was not significantly altered by differentiation of ICSBP-/-progenitor cells with these cytokines (p=0. 8, F=0.33, n=6 Figure 2D ).
However, this correlation did not provide a functional connection between ICSBP, Fap-1, and susceptibility to Fasinduced apoptosis. Therefore, additional studies were performed.
ICSBP inversely correlated with inhibition of Fas-induced apoptosis by Fap-1 in myeloid cells:
To investigate the role of Fap-1 in resistance to Fas-induced apoptosis in U937 cells, we employed a previously described peptide which specifically disrupts the Fas:Fap-1 interaction (the SLV peptide) (29) . For these studies, U937 cells were cultured for 48 hours with or without IFNγ. Cells were analyzed for apoptosis with or without treatment with a Fas-agonist antibody, and with SLV or control VLS peptide (28, 29) . We found that treatment of U937 cells with the Fas-agonist antibody did not significantly alter the percent of apoptotic cells, with or without differentiation (p>0.1, n=3) ( Figure 3A) .
However, Fasantibody-induced a significant amount of apoptosis in SLV peptide-treated, IFNγ-differentiated U937 cells (p=0.005, n=3) ( Figure  3A ). These results suggested that Fas-resistance of U937 cells was Fap-1-dependent.
To verify that SLV peptide was interfering with Fas:Fap-1 interaction, lysates from SLV or VLS peptide treated, IFNγ-differentiated U937 cells were immuno-precipitated with an anti-Fasantibody (or control antibody).
Immunoprecipitates were separated by SDS-PAGE and interaction between Fas and Fap-1 was determined by Western blot ( Figure 3B ). This experiment was repeated twice and a representative blot is shown. SLV peptide treatment decreased co-immunoprecipitation of Fap-1 and Fas, and increased Fasphosphorylation.
We next determined whether manipulation of ICSBP-expression in KG1 cells altered Fasinduced apoptosis, using the stable transfectant pools described above. Each experiment was performed with several different pools. We found that Fas-agonist antibody induced significant apoptosis in IFNγ-treated control or ICSBPoverexpressing KG1 cells (p=0.01, n=3) ( Figure  3C ). Differentiation significantly increased Fasinduced apoptosis in ICSBP-overexpressing KG1 cells (p=0.03, n=3). Conversely, ICSBP-knockdown significantly decreased Fas-induced apoptosis in differentiated KG1 transfectants in comparison to control (p<0.001, n=6) ( Figure 3D ). This difference was abolished by treatment with SLV peptide (p=0.13, n=6). Although SLV peptide significantly increased apoptosis in differentiated KG1 transfectants with ICSBPknock-down (p<0.001, n=6), this effect was not seen in control transfectants (p=0.44, n=6). These studies suggested that resistance to Fas-induced apoptosis in cells with relative ICSBP-deficiency was Fap-1-dependent.
We extended these studies to ex vivo differentiated murine myeloid progenitors. Sca1+ cells were isolated from Wt or ICSBP-/-murine bone marrow. Common granulocyte-monocyte progenitors were cultured in GM-CSF, IL3 and SCF, and some cells were differentiated with G-CSF or M-CSF with or without IFNγ for the last 24 hrs.
We found that apoptosis was not significantly different in Wt vs. ICSBP-/-myeloid progenitor cells, with or without Fas-antibody (p=0.14, F=2.2, n=4) ( Figure 4A ). In contrast, Fas-agonist antibody induced significant apoptosis in G-CSF or M-CSF differentiated Wt cells, and this was increased by IFNγ-treatment (p<0.02, n=4). In contrast, Fas-agonist antibody did not induce significant apoptosis in ICSBP-/-cells under any of these cytokine conditions ( Figure 4A ) (p=0.3, n=4). We noted that baseline apoptosis (i.e. without Fas-antibody) was significantly less in ex vivo differentiated ICSBP-/-vs. Wt murine myeloid cells (p<0.001, n=4).
We found that treatment with SLV peptide significantly increased Fas-induced apoptosis in ICSBP-/-cells that had been differentiated with either G-CSF + IFNγ or M-CSF + IFNγ (p< 0.001, n=3) ( Figure 4B ). In these studies, Fasinduced apoptosis in SLV peptide-treated, G-CSF + IFNγ differentiated ICSBP-/-cells was not significantly different than similarly treated Wt cells (p=0.4, n=3). Interestingly, Fas-antibody induced more apoptosis in SLV peptide-treated, M-CSF + IFNγ differentiated ICSBP-/-cells than in similarly treated Wt cells (p=0.001, n=3).
These results suggested that increased Fap-1-expression contributed to Fas-resistance in ICSBP-/-myeloid cells. However, these studies had not demonstrated a direct impact of ICSBP on PTPN13 transcription. Therefore, this issue was specifically addressed.
ICSBP repressed PTPN13 transcription via a cis element in the proximal promoter:
Based on chromatin immunoprecipitation, we hypothesized that there was an ICSBP-binding cis element between 600 to 670 bp in the proximal PTPN13 5' flank.
To investigate this, we generated a series of reporter constructs with 2.0 kb, 1.3 kb, 670 bp and 500 bp of the PTPN13 5' flank. These PTPN13/reporter constructs were cotransfected into U937 cells with a vector to overexpress ICSBP or empty control vector. U937 cells were chosen for these experiments based on their relatively high level of Fap-1-expression. Since our results suggested that Fap-1-expression was functionally relevant to Fas-resistance in IFNγ-treated U937 cells, transfectants were assayed with or without differentiation.
We found that the construct with 2.0 kb of PTPN13 5' flank had significantly more reporter activity than the 1.3 kb construct ( Figure 5A ) (p<0.001, n=3), indicating the presence of a positive cis element between 2.0 and 1.3 kb (region "A" in Figure 5B ). Differentiation of the transfectants abolished the difference in reporter activity between the 2.0 and 1.3 kb constructs. This suggested the positive cis element in region A was not active in differentiated cells. Activity of both of the 2.0 and 1.3 kb constructs was significantly decreased by overexpression of ICSBP (p<0.001, n=3). This implied an ICSBPbinding negative cis element in the common proximal region.
Truncation from 1.3 kb to 670 bp resulted in further loss of promoter activity in undifferentiated transfectants (p<0.0001, n=3). This suggested a second positive cis element within this region (region "B" in Figure 5B ). This conclusion was supported by the observation that repression of the 670 bp construct by overexpressed ICSBP was relatively greater than repression of the 1.3 kb construct. Indeed, overexpressed ICSBP abolished activity of the 670 bp construct in differentiated transfectants. This would be consistent with more efficient ICSBP-repression of the 670 bp construct because there was less transcriptional activation to overcome in comparison to the 1.3 kb construct. This result also suggested that there was an ICSBP-binding negative cis element within the proximal 670 bp PTPN13 5' flank which was not effectively opposed by positive cis elements within this region (the proximal 670 bp is "C" + "D" in Figure 5B) .
Activity of the 500 bp construct was significantly greater than activity of the 670 bp construct in undifferentiated and differentiated transfectants (p<0.001, n=3).
Overexpressed ICSBP did not significantly alter reporter expression from the 500 bp construct (p=0.1, n=3), in contrast to the profound repression of the 670 bp construct. This suggested that the ICSBPbinding negative cis element was eliminated by truncation of the sequence between 500 and 670 bp (i.e. region "C" in Figure 4B) .
Activity of the 500 bp construct decreased with IFNγ (p<0.01, n=3). This implied that positive cis elements in the proximal 500 bp were more active in undifferentiated transfectants, or that there was a negative cis element that was not repressed by ICSBP within this sequence. The observation that the 670 bp construct was significantly less active than the 500 bp construct suggested that positive cis elements in the proximal 500 bp of PTPN13 5' flank (region "D" in Figure 5B ) were overwhelmed by the ICSBP-binding, negative cis element between 500 and 670 bp (region "C"). Neither
IFNγ-differentiation nor ICSBPoverexpression altered activity of the empty, control reporter vector, which was consistently low (<200 CPM) and was subtracted as background.
These results suggested that the -500 to -670 bp region of the PTPN13 5' flank included an ICSBPbinding repressor element. The most highly conserved sequence within this region was 100% identical in human, mouse and dog and included an IRF-binding consensus (-627 and -587 bp) ( Figure 5C ). Therefore, we hypothesized that the ICSBP-binding repressor cis element was -627 to -527 bp of the PTPN13 5' flank. However, we had not specifically demonstrated ICSBP-binding to this sequence. Therefore, further studies were performed. ICSBP bound to the proximal PTPN13 promoter in a differentiation-stage-specific manner:
We investigated in vivo ICSBP-binding to the putative PTPN13 cis element using chromatin immunoprecipitation from U937 cells.
Coprecipitated chromatin was quantitated by real time PCR with a primer set designed to amplify this region of the promoter (-639 to -567 bp). We found that differentiation significantly increased in vivo binding of endogenous ICSBP to this region of the PTPN13 promoter (p<0.0001, n=6) ( Figure  6A ).
This promoter sequence did not coprecipitate from U937 lysates with pre-immune serum.
We also used two different in vitro assays to investigate ICSBP-binding to the PTPN13 promoter. We first investigated this interaction using a DNA-co-affinity purification assay. For these studies, nuclear proteins were isolated from untreated, or IFNγ-differentiated U937 cells. Proteins were incubated with a biotin labeled, double stranded oligonucleotide probe representing the -587 to -627 bp sequence from the PTPN13 promoter.
In control experiments, proteins were incubated with a biotin labeled, double stranded oligonucleotide containing a mutant PRDI sequence, known not to bind ICSBP (14) . The double stranded oligonucleotides were precipitated and co-precipitating proteins separated by SDS-PAGE. Western blots were probed with an antibody to ICSBP to identify coprecipitating proteins. Non-precipitated nuclear proteins were a control for protein equivalence between the preparations in these experiments.
We found specific interaction of ICSBP with the PTPN13 cis element probe ( Figure 6B ). Consistent with our in vivo results, co-precipitation of ICSBP with the PTPN13 cis element was more efficient with nuclear proteins from differentiated U937 cells. This experiment was repeated with two different batches of nuclear proteins and a representative blot is shown.
We also investigated in vitro ICSBP-binding to the PTPN13 cis element by electrophoretic mobility shift assays (EMSA). For these studies, U937 nuclear proteins were incubated with a radio-labeled, double stranded oligonucleotide probe representing the PTPN13 -587 to -627 bp sequence.
Some binding assays were preincubated with unlabeled, double stranded oligonucleotide competitors representing homologous sequence, an ISRE consensus, or an irrelevant oligonucleotide ( Figure 6C) . A specific protein complex bound to this PTPN13 sequence and exhibited cross-competitive binding specificity with the ISRE-consensus. This complex was relatively more abundant in assays with nuclear proteins from differentiated U937 cells in comparison to undifferentiated cells. Equivalence in protein loading between nuclear protein preparations from was determined in control EMSA with a CCAAT box binding oligonucleotide ( Figure 6C ). These studies were performed with three different batches of nuclear proteins and representative experiments are shown.
To determine whether the complex which bound the PTPN13 probe included ICSBP, nuclear proteins were pre-incubated with either ICSBPantibody or irrelevant control antibody. We found that ICSBP-antibody disrupted the protein complex which bound to the -587 to -627 bp probe ( Figure 6C) . Therefore, these studies suggested that ICSBP interacted with this ISRE-like sequence in the PTPN13 promoter.
ICSBP interacted with the PTPN13 cis element in a tyrosine-phosphorylation dependent manner:
These studies indicated that interaction of ICSBP with the PTPN13 cis element increased during differentiation. The mechanism for this was not obvious, since differentiation of U937 or KG1 cells did not increase ICSBP-expression. We previously found that interaction of ICSBP with the CYBB, NCF2 and NF1 genes increased during differentiation (5, 9, 14) . For these genes, ICSBPbinding was regulated by phosphorylation of conserved tyrosine residues in the ICSBP IRFdomain (9, 10).
Since ICSBP-tyrosinephosphorylation occurs during myelopoiesis (3, 9, 10), this provided a mechanism for differentiation-stage-specific regulation of these target-genes.
Therefore, we performed transfection experiments to determine the role of the IRFdomain tyrosines in ICSBP-induced PTPN13-repression. For these studies, U937 cells were cotransfected with the 2.0 kb PTPN13 reporter construct (or control vector), and vectors to overexpress ICSBP, a form of ICSBP with the conserved IRF-domain tyrosine residues mutated to phenylalanine (Y92/95F ICSBP), or empty control vector. Reporter activity was determined with or without IFNγ-induced differentiation. We found that overexpressed Wt ICSBP repressed PTPN13 promoter-activity significantly more efficiently than Y92/95F ICSBP, with or without differentiation (p<0.0002, n=6) ( Figure 7A ).
Overexpression of these proteins did not alter activity of the control, empty reporter vector, which was subtracted as background. In previous studies, we demonstrated that these two forms of ICSBP were equivalently expressed in U937 cells and equivalently stable under the conditions of these assays (9, 10, 18) . In those studies, we also determined that overexpressed ICSBP is somewhat tyrosine-phosphorylated in U937 transfectants, and tyrosine phosphorylation increased with IFNγ-induced differentiation (9, 10).
We were also interested in the role of IRFdomain tyrosine residues on ICSBP-induced repression of endogenous Fap-1 expression. Previously, we found that expression of Wt ICSBP in ICSBP-/-myeloid cells rescued expression of gp91 PHOX and Nf1, but expression of Y92/95F ICSBP did not (9, 10) . Similar to those studies, ICSBP-/-myeloid progenitors were cultured in GM-CSF, IL3 and SCF, transduced with a retroviral vector to express ICSBP, Y92/95F ICSBP or with empty control vector, and differentiated with M-CSF + IFNγ (as in (10)). Fap-1-expression was determined by real time PCR ( Figure 7B) .
We found that Fap-1-expression was not significantly different in ICSBP-/-cells that had been transduced with empty control vector in comparison to non-transduced ICSBP-/-cells (p<0.02, n=3). Fap-1-expression was also not significantly different in cells that were transduced with a Y92/95F ICSBP expression vector in comparison to empty vector control (p=0.3, n=3). In contrast, ICSBP-/-cells that were transduced with a vector to express Wt ICSBP had significantly less Fap-1 expression in comparison to these other groups (p=0.007, n=3). Expression of Fap-1 in these cells was not significantly different than in Wt cells (p=0.02, n=3).
In control experiments, we verified that Wt and Y92/95F ICSBP were equivalently expressed in transduced ICSBP-/-cells. For these studies, we performed real time PCR with a set of primers designed to amplify the product of either the Wt or mutant ICSBP transgene (see (38) ). We found equivalent expression of Wt and Y92/95F ICSBP in ICSBP-/-cells (p=0.9, n=3) ( Figure 7B ). As anticipated, no transgene was detected in control cells that were transduced with empty retroviral vector. These results were consistent with protein expression results in our previous studies (10) .
We were also interested in determining the role of the conserved IRF-domain tyrosine residues in ICSBP-binding to the PTPN13 promoter in vivo. To do this, aliquots of these transduced ICSBP-/-cells were used for chromatin immunoprecipitation studies.
Chromatin that coprecipitated with ICSBP-antibody (or irrelevant control antibody) was analyzed by real time PCR with primers flanking the ICSBP-binding site in the PTPN13 promoter.
We found that significantly more Wt ICSBP bound to the PTPN13 cis element in comparison to Y92/95F ICSBP (p<0.0001, n= 3). No ICSBP binding to the PTPN13 cis element was detected in control ICSBP-/-cells that had been transduced with empty retroviral vector, as anticipated. In contrast, the PTPN13 cis element did not co-precipitate with control, pre immune serum.
Discussion
Although ICSBP-deficient myeloid cells were known to be apoptosis-resistant (21), direct targetgenes involved in this effect had not been previously identified. In the current studies, we used high throughput screening to identify the gene encoding Fap-1 as an ICSBP target-gene. This was of interest, because Fasdephosphorylation by Fap-1 impairs Fas-induced apoptosis. We found that ICSBP interacted with the PTPN13 promoter in a tyrosine phosphorylation-dependent manner and repressed transcription. We also found that decreased ICSBP-expression increased Fap-1-expression and Fap-1-dependent resistance to Fas-induced apoptosis. Therefore, the current studies identified a pathway involved in apoptosis-resistance in myeloid malignancies which are characterized by decreased ICSBP-expression.
Most previously identified ICSBP-targetgenes encoded proteins involved in the phagocyte or B-cell immune response. Our high throughput screening identified a number of additional genes consistent with this well described function of ICSBP. However, the goal of these studies was to better understand mechanisms for the ICSBPleukemia-suppressor effect. Therefore, we were especially interested to identify a CpG island -875 bp from PTPN13 exon 1. Using additional chromatin immunoprecipitation studies, in vitro binding assays, and transfection experiments, we identified an ICSBP-binding cis element between -627 and -587 bp in the PTPN13 5' flank. This region of the promoter included a highly conserved sequence with homology to both ISRE and composite ets/IRF sequences for IRF-protein DNA-binding.
However, these results did not exclude the possibility that ICSBP also interacted with other cis elements, more remote from the TSS. Since our goal was to identify ICSBP-target-genes functionally involved in leukemia-suppression, we did not exhaustively investigate the PTPN13 locus for additional binding sites. Also, we found that conservation of the PTPN13 5' flank between human, mouse and dog declined rapidly at beyond -2.0 kb from the TSS. This decreased the possibility of additional, functionally significant ICSBP-binding cis elements further 5'.
We found that in vitro and in vivo binding of endogenous ICSBP to the PTPN13 cis element increased during myeloid differentiation. Consistent with this, the impact of ICSBPdeficiency on Fap-1-expression and apoptosisinhibition was greatest in differentiated primary myeloid cells or cell lines. Therefore, these studies identified a mechanism for differentiationstage-inappropriate resistance to Fas-induced apoptosis in ICSBP-deficient cells. There are several mechanisms which might account for increased interaction of endogenous ICSBP with the PTPN13 cis element during myelopoiesis. One possibility was that increased ICSBPexpression during differentiation increased PTPN13-binding. This would be consistent with our transfection experiments in which overexpressed ICSBP repressed PTPN13
transcription. However, ICSBP-expression is not significantly altered by differentiation of myeloid leukemia cell lines or primary murine myeloid progenitors (and (5, 10)). Another possible mechanism by which differentiation might increase ICSBP-interaction with the PTPN13 promoter is post translational modification.
Previous studies found that endogenous ICSBP is tyrosine phosphorylated during differentiation of various myeloid cell lines or murine myeloid progenitors (9, 10). We previously found that phosphorylation of conserved tyrosine residues in the IRF-domain of ICSBP was required for assembly of multi-protein complexes which activate the CYBB, NCF2 and NF1 genes (9, 18) . In the current studies we found that the same IRF-domain tyrosines were involved in differentiation-stage-specific ICSBP-binding to, and repression of, the PTPN13 promoter. Therefore, these studies represent identification of the first target-gene for which ICSBP-tyrosinephosphorylation regulates repression-activity in differentiating myeloid cells.
Although IRF-domain-tyrosine-mutant ICSBP was less efficient at repressing the PTPN13 promoter than Wt ICSBP, repression activity was not abolished. One possible explanation was that phosphorylation of these residues increases ICSBP-affinity for the PTPN13 cis element, but is not an absolute requirement. In this case, the overexpressed mutant protein might have decreased, but not absent, interaction with the cis element. This would be consistent with our studies of ICSBP-interaction with positive cis elements in other target-genes (9, 10, 18) . Another possibility would be that other ICSBP-phosphoresidues, in addition to the IRF-domain tyrosines, are involved in PTPN13-regulation. Identification of ICSBP-partner-proteins will facilitate investigation of these possibilities.
PTPN13 may share a common, bi-directional promoter with the gene which encodes Jnk3 (MAPK10) (34) . These two genes are "head to head" with PTPN13 transcription proceeding telomeric and MAPK10 transcription centromeric. Jnk3 is a stress activated protein kinase with neural cell expression (35) . We found low levels of Jnk3 protein in myeloid leukemia cell lines, with or without differentiation (not shown). These results suggested that the choice between transcription of PTPN13 vs. MAPK10 may be dictated in a tissue specific manner. It will be of interest to investigate this hypothesis further.
We found little Fas-induced apoptosis in U937 cells. However, treatment of U937 cells with the SLV peptide induced Fas-sensitivity which was comparable to KG1 cells. ICSBP-overexpression increased, and knock-down inhibited, Fas-induced apoptosis in KG1 cells. Also, there was no significant difference in Fas-induced apoptosis in IFNγ-treated KG1 cells with ICSBP knock-down + SLV peptide vs. IFNγ-treated control KG1 cells. Therefore, ICSBP influenced Fas-induced apoptosis by dose dependent alteration of Fap-1-expression.
Although ex vivo differentiated Wt primary murine myeloid cells exhibited Fas-induced apoptosis, there was also significant apoptosis in these cells without Fas-antibody (i.e. "endogenous" apoptosis). Ex vivo differentiated ICSBP-/-myeloid cells exhibited less Fas-induced and endogenous apoptosis than Wt cells. These results suggested that ICSBP also influences transcription of target-genes involved in endogenous apoptosis. This would be consistent with the function of several putative ICSBP targetgenes we identified using this screening technique. The significance of ICSBP-regulated transcription of these genes is currently under investigation and will be the subject of future reports.
Treatment of ex vivo differentiated ICSBP-/-granulocytes or monocytes with SLV peptide abolished the difference in Fas-induced apoptosis between these cells and Wt cells. In fact, Fasantibody induced more apoptosis in SLV peptidetreated, monocyte-differentiated ICSBP-/-cells than in similarly treated Wt cells. This implied that other components in the Fas-pathway might be up-regulated in cells with constitutive ICSBPdeficiency. This would be consistent with studies of apoptosis-resistance of chronic phase CML cells (35) . These results also suggested that interference with Fas/Fap-1 interaction might be a profitable approach to the problem of persistent CML clones.
Our studies indicated that regulation of PTPN13-transcription is dependent upon both abundance and tyrosine phosphorylation of ICSBP.
PTPN13-repression by tyrosinephosphorylated ICSBP would permit signaldependent regulation of apoptosis during myelopoiesis. However, abnormal PTPN13-transcription in myeloid malignancies is likely to be related to decreased ICSBP-expression levels. These results suggested that leukemia-associated mutations which impaired ICSBP-tyrosinephosphorylation might synergize with decreased ICSBP-expression for disease progression in myeloid malignancy.
Fas plays other roles in addition to apoptosisregulation during myelopoiesis. Fas may be involved expansion of hematopoietic stem cells (36) . A role for Fap-1 in this process would be of interest. Fas is also involved in phagocyte recruitment to sites of inflammation (37) . If Fap-1 antagonizes this activity, one would anticipate decreased recruitment in ICSBP-deficient malignancies such as CML and tMDS. This might provide a mechanism for the impaired innate immune response in these diseases, despite normal or elevated numbers of mature appearing neutrophils. Such an association might also provide a mechanism for abnormal cell migration in CML.
Therefore, ICSBP-deficiency may impact multiple pathways involved in the innate immune response in myeloid malignancies such as CML and MDS. Chromatin immuno-precipitation was performed using lysates from IFNγ-differentiated U937 cells and antibody to ICSBP or control pre immune serum. Co-precipitating chromatin was amplified by PCR with primer sets representing the proximal 2.0, 1.0, 0.67, 0.60 and 0.50 kb of 5' flank, and products were sized on acrylamide gels. PCR was also performed with a primer set to amplify the sequence between 670 bp and 2.0 kb from the PTPN13 TSS. Stable KG1 transfectant pools were generated with a vector to overexpress ICSBP or with empty control vector, as above. Cells were analyzed for apoptosis, with or without IFNγ-differentiation, with or without Fas-agonist antibody. Statistically significant differences in apoptosis are indicated by *, ** and ***. D. ICSBP knock-down inhibited Fas-induced apoptosis in KG1 cells in a Fap-1-dependent manner. Stable KG1 transfectant pools, described above, were generated with a vector to express an ICSBP-specific shRNA or scrambled shRNA control. Cells were analyzed for apoptosis, with or without IFNγ-differentiation, with or without Fas-agonist antibody. Statistically significant difference in Fas-induced apoptosis are indicated by *or **. Sequences from the proximal PTPN13 promoters of human, mouse and dog in the region of the putative ICSBP-repression cis element were aligned. Conserved sequences are underlined. The IRF-DNA binding consensus sequence in this region of the promoter is in red. bp sequence from the PTPN13 promoter. DNA-affinity purification was performed with nuclear proteins from U937 cells and a double stranded, biotin labeled probe representing the -587 to -627 bp sequence from the PTPN13 promoter, or a non-ICSBP-binding mutant PRDI consensus sequence. Oligonucleotides were precipitated with avidin-conjugated agarose and precipitates were separated by SDS-PAGE. Western blots were probed with an antibody to ICSBP. A 1/10 volume of input (non-precipitated) nuclear proteins was a loading control in this experiment. C. ICSBP specifically interacted with the -587 to -627 bp sequence from the PTPN13 promoter by electrophoretic mobility shift assay. EMSA were performed with U937 cell nuclear proteins and a double stranded, radio-labeled probe representing the -587 to -627 bp sequence from the PTPN13 promoter. Nuclear proteins from IFNγ-differentiated cells were compared to untreated cells. Some binding assays were pre-incubated with excess unlabeled double stranded oligonucleotide competitor representing the homologous sequence, a consensus ISRE sequence, or an irrelevant sequence, as indicated. Other binding assays were pre-incubated with ICSBP-antibody or pre-immune serum. Equal protein loading in assays with nuclear proteins from untreated vs. IFNγ-differentiated U937 cells was determined in control EMSA with a CCAAT box probe. 
